Proteomic-guided targeted treatment of leukoencephalopathy with calcification and cysts

Clicks: 13
ID: 328488
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #429 of 456 articles by views in Brain research

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 456 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Precision therapeutic approaches for rare neurological diseases are often hampered by a limited molecular understanding of the disease. Here, we report the first application of spatially-resolved proteomics to guide targeted treatment in a monogenic leukoencephalopathy. We investigated leukoencephalopathy with calcifications and cysts (LCC), a rare ribosomopathy caused by biallelic mutations in SNORD118 that leads to progressive cerebral white matter degeneration and vascular proliferation. LCC is currently incurable, though understanding the pathogenesis at the proteomic level can offer novel treatment options. We analyzed defined regions of vasculature and white matter from four LCC patients and four healthy controls using laser-capture microdissection followed by label-free mass spectrometry. This spatial proteomic approach revealed distinct, tissue-specific molecular alterations in vasculature and white matter from LCC patients, with dysregulation centered on pathways related to cytoskeleton organisation. Vascular remodeling indicated the primary site of cell proliferation, while leukoencephalopathy appeared driven by ribosomal dysfunction. Notably, VEGFR1/2 and their downstream effectors, including PKC and Ras-MEK-ERK signaling cascades, were consistently upregulated across compartments, highlighting VEGF signaling as a convergent and targetable pathway. In a 53-year-old patient harboring novel compound heterozygous SNORD118 variants, VEGF-targeted treatment with axitinib resulted in sustained radiographic and clinical response for over 35 months, representing the longest therapeutic response reported in LCC to date. This work showcases a proteomics-based framework for mechanism-driven therapy selection in ultra-rare neurological diseases. It further adds to the established genetic drivers of LCC and provides experimental data supporting VEGF pathway modulation as a rational therapeutic strategy in LCC.
Reference Key
openalex_W7212219789 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Nils Briel, Alexander Köpp, Hanna Maria Meister, Marcel Bühler, Tommaso Nicoletti, Sabrina Zechel, Christine Stadelmann, Martin W. Huellner, Dennis Kraemer, Émilie Le Rhun, Tibor Hortbagyi, Menno R Germans, Zsolt Kulcsár, Parisa Amini, Enni Markkanen, Philipp Valko, Roman Sankowski, Hans H. Jung, Michael Weller, K Schubert, Tobias Weiß
Are you one of these authors? Claim your profile
Journal Brain research
Year 2026
DOI
10.1093/brain/awag299
URL
https://academic.oup.com/brain/advance-article-pdf/doi/10.1093/brain/awag299/71031247/awag299.pdf
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.